

Emmanuelle Clappier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1004220/publications.pdf>

Version: 2024-02-01

37
papers

1,058
citations

686830

13
h-index

433756

31
g-index

37
all docs

37
docs citations

37
times ranked

2162
citing authors

#	ARTICLE	IF	CITATIONS
1	A landscape of germ line mutations in a cohort of inherited bone marrow failure patients. <i>Blood</i> , 2018, 131, 717-732.	0.6	240
2	Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia. <i>Haematologica</i> , 2015, 100, 1301-1310.	1.7	151
3	Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements. <i>Blood</i> , 2019, 134, 1351-1355.	0.6	89
4	Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2021, 35, 3383-3393.	3.3	77
5	ZEB2 drives immature T-cell lymphoblastic leukaemia development via enhanced tumour-initiating potential and IL-7 receptor signalling. <i>Nature Communications</i> , 2015, 6, 5794.	5.8	75
6	<i>UBA1</i> Variations in Neutrophilic Dermatitis Skin Lesions of Patients With VEXAS Syndrome. <i>JAMA Dermatology</i> , 2021, 157, 1349.	2.0	71
7	PAX5 P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcome. <i>Blood</i> , 2019, 133, 280-284.	0.6	48
8	Actinomycin D Targets NPM1c-Primed Mitochondria to Restore PML-Driven Senescence in AML Therapy. <i>Cancer Discovery</i> , 2021, 11, 3198-3213.	7.7	38
9	<i>NUP214-ABL1</i> fusion defines a rare subtype of B-cell precursor acute lymphoblastic leukemia that could benefit from tyrosine kinase inhibitors. <i>Haematologica</i> , 2016, 101, e133-e134.	1.7	35
10	Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease. <i>Leukemia</i> , 2021, 35, 2720-2724.	3.3	29
11	B-ALL With t(5;14)(q31;q32); IGH-IL3 Rearrangement and Eosinophilia: A Comprehensive Analysis of a Peculiar IGH-Rearranged B-ALL. <i>Frontiers in Oncology</i> , 2019, 9, 1374.	1.3	28
12	Prevalence of UBA1 mutations in MDS/CMML patients with systemic inflammatory and auto-immune disease. <i>Leukemia</i> , 2021, 35, 2731-2733.	3.3	27
13	Next-Generation Sequencing in Myeloid Neoplasm-Associated Sweet's Syndrome Demonstrates Clonal Relation between Malignant Cells and Skin-Infiltrating Neutrophils. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1873-1876.e5.	0.3	23
14	Minimal residual disease quantification in ovarian tissue collected from patients in complete remission of acute leukemia. <i>Blood</i> , 2021, 137, 1697-1701.	0.6	15
15	Clinical, pathological, and molecular features of myelodysplasia cutis. <i>Blood</i> , 2022, 139, 1251-1253.	0.6	15
16	Early detection of <i>WT1</i> measurable residual disease identifies high-risk patients, independent of transplantation in AML. <i>Blood Advances</i> , 2021, 5, 5258-5268.	2.5	12
17	Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy. <i>Leukemia</i> , 2021, 35, 712-723.	3.3	10
18	Fractionated Inotuzumab Ozogamicin Combined with Low-Intensity Chemotherapy Provides Very Good Outcome in Older Patients with Newly Diagnosed CD22+ Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia: First Results from the EWALL-INO Study. <i>Blood</i> , 2021, 138, 511-511.	0.6	10

#	ARTICLE	IF	CITATIONS
19	High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL. <i>Haematologica</i> , 2022, , .	1.7	10
20	Should Transplantation Still Be Considered for Ph1-Negative Myeloproliferative Neoplasms in Transformation?. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1160-1170.	2.0	9
21	Safety and Efficacy of Tisagenlecleucel (CTLO19) in B-Cell Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults: The French Experience. <i>Blood</i> , 2019, 134, 3876-3876.	0.6	9
22	CD200/BTLA deletions in pediatric precursor B-cell acute lymphoblastic leukemia treated according to the EORTC-CLG 58951 protocol. <i>Haematologica</i> , 2015, 100, 1311-1319.	1.7	8
23	Outcome and clinicophenotypical features of acute lymphoblastic leukemia/lymphoblastic lymphoma with cutaneous involvement: A multicenter case series. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1166-1170.	0.6	6
24	Biological Effects of BET Inhibition by OTX015 (MK-8628) and JQ1 in NPM1-Mutated (NPM1c) Acute Myeloid Leukemia (AML). <i>Biomedicines</i> , 2021, 9, 1704.	1.4	5
25	Niche-like Ex Vivo High Throughput (NEXT) Drug Screening Platform in Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 12-13.	0.6	4
26	T-Cell Acute Lymphoblastic Leukemia in a Young Adult With Thrombocytopenia-absent Radius Syndrome: A Case Report and Review of the Literature. <i>Journal of Pediatric Hematology/Oncology</i> , 2021, 43, 232-235.	0.3	3
27	Frequency and Outcome of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with BCR-ABL1 Clonal Hematopoiesis after Blast Clearance: Results from the Graaph-2014 Trial. <i>Blood</i> , 2021, 138, 3478-3478.	0.6	3
28	MDS/CMML with <i>TET2</i> or <i>IDH</i> mutation Are Associated with Systemic Inflammatory and Autoimmune Diseases (SIAD) and T Cell Dysregulation. <i>Blood</i> , 2020, 136, 31-32.	0.6	3
29	Common clonal origin of an EBV-positive diffuse large B cell lymphoma and a chronic myelomonocytic leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 3327-3329.	0.6	1
30	Multicenter Next-Generation Sequencing Studies between Theory and Practice. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 347-357.	1.2	1
31	Prognostic Impact of Clonal Diversity in Acute Myeloid Leukemia (AML) Treated with Intensive Chemotherapy (IC). <i>Blood</i> , 2019, 134, 2700-2700.	0.6	1
32	ERG Intragenic Deletion Characterizes a Distinct Oncogenic Subtype of B-Cell Precursor Acute Lymphoblastic Leukemia with a Favourable Outcome Despite Frequent IKZF1 Deletions. <i>Blood</i> , 2012, 120, 121-121.	0.6	1
33	Clinical and Molecular Characteristics of DDX41-Mutated Patients in a Large Cohort of Sporadic MDS/AML. <i>Blood</i> , 2018, 132, 797-797.	0.6	1
34	Ikaros deficiency is associated with aggressive BCR-ABL1 B-cell precursor acute lymphoblastic leukemia independent of the lineage and developmental origin. <i>Haematologica</i> , 2022, 107, 316-320.	1.7	0
35	Cyclin D2 Dysregulation by Chromosomal Translocations to TCR Loci in T-Cell Acute Lymphoblastic Leukemia (T-ALL).. <i>Blood</i> , 2006, 108, 2073-2073.	0.6	0
36	Minimal Residual Disease in Ovarian Biopsies Collected in Patients with Bone Marrow Complete Remission of Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 916-916.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Intra-Tumor Heterogeneity in Acute Myeloid Leukemia (AML): Results from a Real Life Cohort. Blood, 2018, 132, 1537-1537.	0.6	0